Iteos Therapeutics Inc Cash Flow-to-Debt Ratio
Iteos Therapeutics Inc cash flow-to-debt ratio. Iteos Therapeutics Inc (ITOS) has a Cash Flow-to-Debt Ratio of -0.33x as of June 2025, meaning its operating cash flow of $-42.45 Million could theoretically repay 0% of its total liabilities ($129.28 Million) in one year. Check Iteos Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Iteos Therapeutics Inc (2018–2024)
Cash flow-to-debt ratio of Iteos Therapeutics Inc from 2018 to 2024. Historical debt coverage capacity for Iteos Therapeutics Inc across 7 annual periods. Check ITOS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Iteos Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2024)
Iteos Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for Iteos Therapeutics Inc. For the full cash flow conversion analysis, see ITOS cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.02x | $-98.18 Million | $96.68 Million | ▲ +9.6% |
| 2023 | -1.12x | $-103.76 Million | $92.36 Million | ▲ +7.4% |
| 2022 | -1.21x | $-111.19 Million | $91.66 Million | ▼ -178.5% |
| 2021 | 1.55x | $513.14 Million | $331.89 Million | ▲ +231.2% |
| 2020 | -1.18x | $-25.18 Million | $21.36 Million | ▲ +23.2% |
| 2019 | -1.54x | $-23.14 Million | $15.07 Million | ▲ +0.8% |
| 2018 | -1.55x | $-19.10 Million | $12.34 Million | — |